Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin (FSH/LH preparation) presented as an injection solution for subcutaneous use. It is employed to treat female infertility by stimulating ovarian follicular development and promoting ovulation.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable cold‑chain logistics for this biologic product, benefiting clients with consistent batch release and regulatory support across multiple markets.

Menopur is a gonadotropin used in reproductive medicine to stimulate ovarian activity.

- Induction of ovulation: facilitates follicular growth and ovulation in women with anovulatory infertility. - Controlled ovarian stimulation: supports multiple follicle development for IVF cycles. - Assisted reproductive technology (IUI): enhances follicular response for intrauterine insemination procedures.

Menopur may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain or redness - Abdominal bloating or discomfort - Nausea - Headache

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS) - Multiple pregnancy - Severe allergic reaction (anaphylaxis) - Ovarian torsion

When using Menopur, careful monitoring and patient assessment are essential.

- Monitor ovarian response: use ultrasound and estradiol levels to adjust dose. - Avoid use in pregnancy: contraindicated due to fetal risk. - Assess for hypersensitivity: discontinue if allergic reaction occurs. - Use caution in patients with ovarian cysts or polycystic ovary syndrome. - Adjust dosing in renal or hepatic impairment: consider reduced dose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur may interact with other medications that affect hormonal pathways or coagulation.

Major Interactions (Avoid): - GnRH agonists or antagonists: may blunt ovarian response. - Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may influence ovarian sensitivity. - Corticosteroids: can alter hormone metabolism and affect response. - Anticoagulants: increased risk of ovarian bleeding in OHSS. - Antidiabetic agents: monitor glucose as hormonal changes may affect control.